Skip to main content

Fiscal Wizard · Single-issue tearsheet

GPCR / Jun 21, 2026 Run #7553

GPCR

Structure Therapeutics Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Composite verdict

F 13.9 / 100
Bearish setup · Mean Reversion 11 drivers · 4 gates blocking
  • Stochastic Cross
  • Williams %R
  • Bollinger Reentry
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 379th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 17 signals100% Bear
Momentum Neutral 46Mean-reversion Bearish 5

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -73%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

27.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Return on Assets 79
Margin of Safety 0
Greenblatt ROC 79
Free Cash Flow Yield 0
Return on Capital Employed 79
EPS Growth (YoY) 0

Technicals Bearish

0.4 / 100

Bearish setup leads (Stochastic Cross, Williams %R, Bollinger Reentry); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Stochastic Cross 7
Williams %R 15
Bollinger Reentry 18

Risk Gates

4 blocking 3 caution

4 guards active, 23 signals gated.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for GPCR.